Real-world use of an MS blood test shows how it helps monitor disease activity and guide treatment decisions in U.S. patients ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American ...

This segment highlights the role of clinical guidelines in shaping treatment decisions in advanced melanoma, particularly ...

The death of a charity supporter who died in hospital after suffering a cardiac arrest may not have happened if she had been ...

Voters cast ballots on a state constitutional amendment that would pave the way for a new congressional map designed to help ...

The trial compared hospital stay duration of severely burned patients treated with intact fish-skin grafts and patients ...

Neurologist visit frequency was modestly higher among cancer cases than controls but declined over time in both settings, with no meaningful pre/post-cancer change in incident rate ratios.

Medically integrated dispensing improves affordability, adherence, and toxicity management via embedded pharmacy teams, ...

Add The New York Times on GoogleAgrega The New York Times en Google Some 60 years ago, American legislators set out to tackle ...

These results underscore that fenebrutinib has potential as a high-efficacy oral treatment for RMS. Its unique mode of action may offer a differentiated profile by targeting dual drivers of MS within ...

Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 monthsTop-line data expected year-end ...

Chronic constipation is becoming a common issue lately with most people unable to identify the problem on time Learn ...